Search Results
1
Study Matches
A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy
This is a study of tisagenlecleucel of for high risk B-cell acute lymphoblastic leukemia in children and young adults. The goal is to find out how safe it is and how well it works.
Tisagenlecleucel is a kind of medicine made up of cells (a "cell therapy"). It is made by taking immune cells called T cells (a type of white blood cell) and changing them in a lab in way that makes them able to find and destroy cancer cells.
Suzanne Treadway at streadway@pennstatehealth.psu.edu or 717-531-3097
All
All
NCT03876769
Cancer